N8 Medical is a clinical-stage medical device company focused upon commercializing antimicrobial medical devices and coatings to address the multi-billion dollar public health and economic burden associated with medical device-related hospital acquired infections (“HAIs”). N8 Medical’s business is based on the application of a novel, proprietary class of compounds known as ceragenins or CSAs (“ceragenins” or “CSAs”) to medical devices for the purpose of transforming existing medical devices into high value devices with antimicrobial, anti-inflammatory and other therapeutic properties that improve patient outcomes and lower the overall cost of care. In April 2017, FDA granted our request to designate our CeraShield™ drug-eluting endotracheal tube as a "breakthrough device" pursuant to the 21st Century Cures Act. We expect IDE approval in February 2018. For more information about N8 Medical, please see www.n8medical.com.